The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Anti-TIGIT Antibody Market Research Report 2025
Synopsis
A human monoclonal antibody targeting the co-inhibitory molecule and immune checkpoint inhibitor T-cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT), with potential immune checkpoint inhibitory activity.
The global Anti-TIGIT Antibody market was valued at US$ 324.8 million in 2023 and is anticipated to reach US$ 787.1 million by 2030, witnessing a CAGR of 13.5% during the forecast period 2024-2030.
TIGIT (T cell immunoreceptor with Ig and ITIM domains) is a protein receptor found on various immune cells, including T cells and natural killer (NK) cells. It plays a role in regulating immune responses, and targeting TIGIT has emerged as a potential therapeutic strategy for cancer and autoimmune diseases.
Clinical trials were underway to evaluate the safety and efficacy of anti-TIGIT antibodies either as monotherapy or in combination with other immunotherapies, such as checkpoint inhibitors (e.g., anti-PD-1/PD-L1 antibodies). Promising results were reported from early-stage trials, showing potential benefits in various solid tumors, including lung cancer, melanoma, and gastrointestinal cancers.
The market for anti-TIGIT antibodies was expected to grow as more clinical data became available.
This report aims to provide a comprehensive presentation of the global market for Anti-TIGIT Antibody, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Anti-TIGIT Antibody.
Report Scope
The Anti-TIGIT Antibody market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Anti-TIGIT Antibody market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Anti-TIGIT Antibody companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Roche
Merck
AstraZeneca
Arcus
Astellas
BeiGene
BMS
Junshi Biosciences
Innovent Biologics
Mereo BioPharma
Seattle Genetics
Hengrui Medicine
Compugen
Gilead Sciences
Segment by Type
Monotherapy
Combination Therapy
Segment by Application
Cell Carcinoma
Solid Tumor
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Anti-TIGIT Antibody companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
A human monoclonal antibody targeting the co-inhibitory molecule and immune checkpoint inhibitor T-cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT), with potential immune checkpoint inhibitory activity.
The global Anti-TIGIT Antibody market was valued at US$ 324.8 million in 2023 and is anticipated to reach US$ 787.1 million by 2030, witnessing a CAGR of 13.5% during the forecast period 2024-2030.
TIGIT (T cell immunoreceptor with Ig and ITIM domains) is a protein receptor found on various immune cells, including T cells and natural killer (NK) cells. It plays a role in regulating immune responses, and targeting TIGIT has emerged as a potential therapeutic strategy for cancer and autoimmune diseases.
Clinical trials were underway to evaluate the safety and efficacy of anti-TIGIT antibodies either as monotherapy or in combination with other immunotherapies, such as checkpoint inhibitors (e.g., anti-PD-1/PD-L1 antibodies). Promising results were reported from early-stage trials, showing potential benefits in various solid tumors, including lung cancer, melanoma, and gastrointestinal cancers.
The market for anti-TIGIT antibodies was expected to grow as more clinical data became available.
This report aims to provide a comprehensive presentation of the global market for Anti-TIGIT Antibody, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Anti-TIGIT Antibody.
Report Scope
The Anti-TIGIT Antibody market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Anti-TIGIT Antibody market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Anti-TIGIT Antibody companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Roche
Merck
AstraZeneca
Arcus
Astellas
BeiGene
BMS
Junshi Biosciences
Innovent Biologics
Mereo BioPharma
Seattle Genetics
Hengrui Medicine
Compugen
Gilead Sciences
Segment by Type
Monotherapy
Combination Therapy
Segment by Application
Cell Carcinoma
Solid Tumor
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Anti-TIGIT Antibody companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Anti-TIGIT Antibody Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Monotherapy
1.2.3 Combination Therapy
1.3 Market by Application
1.3.1 Global Anti-TIGIT Antibody Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Cell Carcinoma
1.3.3 Solid Tumor
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Anti-TIGIT Antibody Market Perspective (2019-2030)
2.2 Anti-TIGIT Antibody Growth Trends by Region
2.2.1 Global Anti-TIGIT Antibody Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Anti-TIGIT Antibody Historic Market Size by Region (2019-2024)
2.2.3 Anti-TIGIT Antibody Forecasted Market Size by Region (2025-2030)
2.3 Anti-TIGIT Antibody Market Dynamics
2.3.1 Anti-TIGIT Antibody Industry Trends
2.3.2 Anti-TIGIT Antibody Market Drivers
2.3.3 Anti-TIGIT Antibody Market Challenges
2.3.4 Anti-TIGIT Antibody Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Anti-TIGIT Antibody Players by Revenue
3.1.1 Global Top Anti-TIGIT Antibody Players by Revenue (2019-2024)
3.1.2 Global Anti-TIGIT Antibody Revenue Market Share by Players (2019-2024)
3.2 Global Anti-TIGIT Antibody Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Anti-TIGIT Antibody Revenue
3.4 Global Anti-TIGIT Antibody Market Concentration Ratio
3.4.1 Global Anti-TIGIT Antibody Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Anti-TIGIT Antibody Revenue in 2023
3.5 Anti-TIGIT Antibody Key Players Head office and Area Served
3.6 Key Players Anti-TIGIT Antibody Product Solution and Service
3.7 Date of Enter into Anti-TIGIT Antibody Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Anti-TIGIT Antibody Breakdown Data by Type
4.1 Global Anti-TIGIT Antibody Historic Market Size by Type (2019-2024)
4.2 Global Anti-TIGIT Antibody Forecasted Market Size by Type (2025-2030)
5 Anti-TIGIT Antibody Breakdown Data by Application
5.1 Global Anti-TIGIT Antibody Historic Market Size by Application (2019-2024)
5.2 Global Anti-TIGIT Antibody Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Anti-TIGIT Antibody Market Size (2019-2030)
6.2 North America Anti-TIGIT Antibody Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Anti-TIGIT Antibody Market Size by Country (2019-2024)
6.4 North America Anti-TIGIT Antibody Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Anti-TIGIT Antibody Market Size (2019-2030)
7.2 Europe Anti-TIGIT Antibody Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Anti-TIGIT Antibody Market Size by Country (2019-2024)
7.4 Europe Anti-TIGIT Antibody Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Anti-TIGIT Antibody Market Size (2019-2030)
8.2 Asia-Pacific Anti-TIGIT Antibody Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Anti-TIGIT Antibody Market Size by Region (2019-2024)
8.4 Asia-Pacific Anti-TIGIT Antibody Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Anti-TIGIT Antibody Market Size (2019-2030)
9.2 Latin America Anti-TIGIT Antibody Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Anti-TIGIT Antibody Market Size by Country (2019-2024)
9.4 Latin America Anti-TIGIT Antibody Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Anti-TIGIT Antibody Market Size (2019-2030)
10.2 Middle East & Africa Anti-TIGIT Antibody Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Anti-TIGIT Antibody Market Size by Country (2019-2024)
10.4 Middle East & Africa Anti-TIGIT Antibody Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Roche
11.1.1 Roche Company Detail
11.1.2 Roche Business Overview
11.1.3 Roche Anti-TIGIT Antibody Introduction
11.1.4 Roche Revenue in Anti-TIGIT Antibody Business (2019-2024)
11.1.5 Roche Recent Development
11.2 Merck
11.2.1 Merck Company Detail
11.2.2 Merck Business Overview
11.2.3 Merck Anti-TIGIT Antibody Introduction
11.2.4 Merck Revenue in Anti-TIGIT Antibody Business (2019-2024)
11.2.5 Merck Recent Development
11.3 AstraZeneca
11.3.1 AstraZeneca Company Detail
11.3.2 AstraZeneca Business Overview
11.3.3 AstraZeneca Anti-TIGIT Antibody Introduction
11.3.4 AstraZeneca Revenue in Anti-TIGIT Antibody Business (2019-2024)
11.3.5 AstraZeneca Recent Development
11.4 Arcus
11.4.1 Arcus Company Detail
11.4.2 Arcus Business Overview
11.4.3 Arcus Anti-TIGIT Antibody Introduction
11.4.4 Arcus Revenue in Anti-TIGIT Antibody Business (2019-2024)
11.4.5 Arcus Recent Development
11.5 Astellas
11.5.1 Astellas Company Detail
11.5.2 Astellas Business Overview
11.5.3 Astellas Anti-TIGIT Antibody Introduction
11.5.4 Astellas Revenue in Anti-TIGIT Antibody Business (2019-2024)
11.5.5 Astellas Recent Development
11.6 BeiGene
11.6.1 BeiGene Company Detail
11.6.2 BeiGene Business Overview
11.6.3 BeiGene Anti-TIGIT Antibody Introduction
11.6.4 BeiGene Revenue in Anti-TIGIT Antibody Business (2019-2024)
11.6.5 BeiGene Recent Development
11.7 BMS
11.7.1 BMS Company Detail
11.7.2 BMS Business Overview
11.7.3 BMS Anti-TIGIT Antibody Introduction
11.7.4 BMS Revenue in Anti-TIGIT Antibody Business (2019-2024)
11.7.5 BMS Recent Development
11.8 Junshi Biosciences
11.8.1 Junshi Biosciences Company Detail
11.8.2 Junshi Biosciences Business Overview
11.8.3 Junshi Biosciences Anti-TIGIT Antibody Introduction
11.8.4 Junshi Biosciences Revenue in Anti-TIGIT Antibody Business (2019-2024)
11.8.5 Junshi Biosciences Recent Development
11.9 Innovent Biologics
11.9.1 Innovent Biologics Company Detail
11.9.2 Innovent Biologics Business Overview
11.9.3 Innovent Biologics Anti-TIGIT Antibody Introduction
11.9.4 Innovent Biologics Revenue in Anti-TIGIT Antibody Business (2019-2024)
11.9.5 Innovent Biologics Recent Development
11.10 Mereo BioPharma
11.10.1 Mereo BioPharma Company Detail
11.10.2 Mereo BioPharma Business Overview
11.10.3 Mereo BioPharma Anti-TIGIT Antibody Introduction
11.10.4 Mereo BioPharma Revenue in Anti-TIGIT Antibody Business (2019-2024)
11.10.5 Mereo BioPharma Recent Development
11.11 Seattle Genetics
11.11.1 Seattle Genetics Company Detail
11.11.2 Seattle Genetics Business Overview
11.11.3 Seattle Genetics Anti-TIGIT Antibody Introduction
11.11.4 Seattle Genetics Revenue in Anti-TIGIT Antibody Business (2019-2024)
11.11.5 Seattle Genetics Recent Development
11.12 Hengrui Medicine
11.12.1 Hengrui Medicine Company Detail
11.12.2 Hengrui Medicine Business Overview
11.12.3 Hengrui Medicine Anti-TIGIT Antibody Introduction
11.12.4 Hengrui Medicine Revenue in Anti-TIGIT Antibody Business (2019-2024)
11.12.5 Hengrui Medicine Recent Development
11.13 Compugen
11.13.1 Compugen Company Detail
11.13.2 Compugen Business Overview
11.13.3 Compugen Anti-TIGIT Antibody Introduction
11.13.4 Compugen Revenue in Anti-TIGIT Antibody Business (2019-2024)
11.13.5 Compugen Recent Development
11.14 Gilead Sciences
11.14.1 Gilead Sciences Company Detail
11.14.2 Gilead Sciences Business Overview
11.14.3 Gilead Sciences Anti-TIGIT Antibody Introduction
11.14.4 Gilead Sciences Revenue in Anti-TIGIT Antibody Business (2019-2024)
11.14.5 Gilead Sciences Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global Anti-TIGIT Antibody Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Monotherapy
Table 3. Key Players of Combination Therapy
Table 4. Global Anti-TIGIT Antibody Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 5. Global Anti-TIGIT Antibody Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 6. Global Anti-TIGIT Antibody Market Size by Region (2019-2024) & (US$ Million)
Table 7. Global Anti-TIGIT Antibody Market Share by Region (2019-2024)
Table 8. Global Anti-TIGIT Antibody Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 9. Global Anti-TIGIT Antibody Market Share by Region (2025-2030)
Table 10. Anti-TIGIT Antibody Market Trends
Table 11. Anti-TIGIT Antibody Market Drivers
Table 12. Anti-TIGIT Antibody Market Challenges
Table 13. Anti-TIGIT Antibody Market Restraints
Table 14. Global Anti-TIGIT Antibody Revenue by Players (2019-2024) & (US$ Million)
Table 15. Global Anti-TIGIT Antibody Market Share by Players (2019-2024)
Table 16. Global Top Anti-TIGIT Antibody Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Anti-TIGIT Antibody as of 2023)
Table 17. Ranking of Global Top Anti-TIGIT Antibody Companies by Revenue (US$ Million) in 2023
Table 18. Global 5 Largest Players Market Share by Anti-TIGIT Antibody Revenue (CR5 and HHI) & (2019-2024)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Anti-TIGIT Antibody Product Solution and Service
Table 21. Date of Enter into Anti-TIGIT Antibody Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Anti-TIGIT Antibody Market Size by Type (2019-2024) & (US$ Million)
Table 24. Global Anti-TIGIT Antibody Revenue Market Share by Type (2019-2024)
Table 25. Global Anti-TIGIT Antibody Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 26. Global Anti-TIGIT Antibody Revenue Market Share by Type (2025-2030)
Table 27. Global Anti-TIGIT Antibody Market Size by Application (2019-2024) & (US$ Million)
Table 28. Global Anti-TIGIT Antibody Revenue Market Share by Application (2019-2024)
Table 29. Global Anti-TIGIT Antibody Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 30. Global Anti-TIGIT Antibody Revenue Market Share by Application (2025-2030)
Table 31. North America Anti-TIGIT Antibody Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 32. North America Anti-TIGIT Antibody Market Size by Country (2019-2024) & (US$ Million)
Table 33. North America Anti-TIGIT Antibody Market Size by Country (2025-2030) & (US$ Million)
Table 34. Europe Anti-TIGIT Antibody Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 35. Europe Anti-TIGIT Antibody Market Size by Country (2019-2024) & (US$ Million)
Table 36. Europe Anti-TIGIT Antibody Market Size by Country (2025-2030) & (US$ Million)
Table 37. Asia-Pacific Anti-TIGIT Antibody Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 38. Asia-Pacific Anti-TIGIT Antibody Market Size by Region (2019-2024) & (US$ Million)
Table 39. Asia-Pacific Anti-TIGIT Antibody Market Size by Region (2025-2030) & (US$ Million)
Table 40. Latin America Anti-TIGIT Antibody Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 41. Latin America Anti-TIGIT Antibody Market Size by Country (2019-2024) & (US$ Million)
Table 42. Latin America Anti-TIGIT Antibody Market Size by Country (2025-2030) & (US$ Million)
Table 43. Middle East & Africa Anti-TIGIT Antibody Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 44. Middle East & Africa Anti-TIGIT Antibody Market Size by Country (2019-2024) & (US$ Million)
Table 45. Middle East & Africa Anti-TIGIT Antibody Market Size by Country (2025-2030) & (US$ Million)
Table 46. Roche Company Detail
Table 47. Roche Business Overview
Table 48. Roche Anti-TIGIT Antibody Product
Table 49. Roche Revenue in Anti-TIGIT Antibody Business (2019-2024) & (US$ Million)
Table 50. Roche Recent Development
Table 51. Merck Company Detail
Table 52. Merck Business Overview
Table 53. Merck Anti-TIGIT Antibody Product
Table 54. Merck Revenue in Anti-TIGIT Antibody Business (2019-2024) & (US$ Million)
Table 55. Merck Recent Development
Table 56. AstraZeneca Company Detail
Table 57. AstraZeneca Business Overview
Table 58. AstraZeneca Anti-TIGIT Antibody Product
Table 59. AstraZeneca Revenue in Anti-TIGIT Antibody Business (2019-2024) & (US$ Million)
Table 60. AstraZeneca Recent Development
Table 61. Arcus Company Detail
Table 62. Arcus Business Overview
Table 63. Arcus Anti-TIGIT Antibody Product
Table 64. Arcus Revenue in Anti-TIGIT Antibody Business (2019-2024) & (US$ Million)
Table 65. Arcus Recent Development
Table 66. Astellas Company Detail
Table 67. Astellas Business Overview
Table 68. Astellas Anti-TIGIT Antibody Product
Table 69. Astellas Revenue in Anti-TIGIT Antibody Business (2019-2024) & (US$ Million)
Table 70. Astellas Recent Development
Table 71. BeiGene Company Detail
Table 72. BeiGene Business Overview
Table 73. BeiGene Anti-TIGIT Antibody Product
Table 74. BeiGene Revenue in Anti-TIGIT Antibody Business (2019-2024) & (US$ Million)
Table 75. BeiGene Recent Development
Table 76. BMS Company Detail
Table 77. BMS Business Overview
Table 78. BMS Anti-TIGIT Antibody Product
Table 79. BMS Revenue in Anti-TIGIT Antibody Business (2019-2024) & (US$ Million)
Table 80. BMS Recent Development
Table 81. Junshi Biosciences Company Detail
Table 82. Junshi Biosciences Business Overview
Table 83. Junshi Biosciences Anti-TIGIT Antibody Product
Table 84. Junshi Biosciences Revenue in Anti-TIGIT Antibody Business (2019-2024) & (US$ Million)
Table 85. Junshi Biosciences Recent Development
Table 86. Innovent Biologics Company Detail
Table 87. Innovent Biologics Business Overview
Table 88. Innovent Biologics Anti-TIGIT Antibody Product
Table 89. Innovent Biologics Revenue in Anti-TIGIT Antibody Business (2019-2024) & (US$ Million)
Table 90. Innovent Biologics Recent Development
Table 91. Mereo BioPharma Company Detail
Table 92. Mereo BioPharma Business Overview
Table 93. Mereo BioPharma Anti-TIGIT Antibody Product
Table 94. Mereo BioPharma Revenue in Anti-TIGIT Antibody Business (2019-2024) & (US$ Million)
Table 95. Mereo BioPharma Recent Development
Table 96. Seattle Genetics Company Detail
Table 97. Seattle Genetics Business Overview
Table 98. Seattle Genetics Anti-TIGIT Antibody Product
Table 99. Seattle Genetics Revenue in Anti-TIGIT Antibody Business (2019-2024) & (US$ Million)
Table 100. Seattle Genetics Recent Development
Table 101. Hengrui Medicine Company Detail
Table 102. Hengrui Medicine Business Overview
Table 103. Hengrui Medicine Anti-TIGIT Antibody Product
Table 104. Hengrui Medicine Revenue in Anti-TIGIT Antibody Business (2019-2024) & (US$ Million)
Table 105. Hengrui Medicine Recent Development
Table 106. Compugen Company Detail
Table 107. Compugen Business Overview
Table 108. Compugen Anti-TIGIT Antibody Product
Table 109. Compugen Revenue in Anti-TIGIT Antibody Business (2019-2024) & (US$ Million)
Table 110. Compugen Recent Development
Table 111. Gilead Sciences Company Detail
Table 112. Gilead Sciences Business Overview
Table 113. Gilead Sciences Anti-TIGIT Antibody Product
Table 114. Gilead Sciences Revenue in Anti-TIGIT Antibody Business (2019-2024) & (US$ Million)
Table 115. Gilead Sciences Recent Development
Table 116. Research Programs/Design for This Report
Table 117. Key Data Information from Secondary Sources
Table 118. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Anti-TIGIT Antibody Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Anti-TIGIT Antibody Market Share by Type: 2023 VS 2030
Figure 3. Monotherapy Features
Figure 4. Combination Therapy Features
Figure 5. Global Anti-TIGIT Antibody Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 6. Global Anti-TIGIT Antibody Market Share by Application: 2023 VS 2030
Figure 7. Cell Carcinoma Case Studies
Figure 8. Solid Tumor Case Studies
Figure 9. Anti-TIGIT Antibody Report Years Considered
Figure 10. Global Anti-TIGIT Antibody Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 11. Global Anti-TIGIT Antibody Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 12. Global Anti-TIGIT Antibody Market Share by Region: 2023 VS 2030
Figure 13. Global Anti-TIGIT Antibody Market Share by Players in 2023
Figure 14. Global Top Anti-TIGIT Antibody Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Anti-TIGIT Antibody as of 2023)
Figure 15. The Top 10 and 5 Players Market Share by Anti-TIGIT Antibody Revenue in 2023
Figure 16. North America Anti-TIGIT Antibody Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 17. North America Anti-TIGIT Antibody Market Share by Country (2019-2030)
Figure 18. United States Anti-TIGIT Antibody Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 19. Canada Anti-TIGIT Antibody Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 20. Europe Anti-TIGIT Antibody Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 21. Europe Anti-TIGIT Antibody Market Share by Country (2019-2030)
Figure 22. Germany Anti-TIGIT Antibody Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 23. France Anti-TIGIT Antibody Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 24. U.K. Anti-TIGIT Antibody Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. Italy Anti-TIGIT Antibody Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. Russia Anti-TIGIT Antibody Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. Nordic Countries Anti-TIGIT Antibody Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. Asia-Pacific Anti-TIGIT Antibody Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Asia-Pacific Anti-TIGIT Antibody Market Share by Region (2019-2030)
Figure 30. China Anti-TIGIT Antibody Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Japan Anti-TIGIT Antibody Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. South Korea Anti-TIGIT Antibody Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. Southeast Asia Anti-TIGIT Antibody Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. India Anti-TIGIT Antibody Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. Australia Anti-TIGIT Antibody Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. Latin America Anti-TIGIT Antibody Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. Latin America Anti-TIGIT Antibody Market Share by Country (2019-2030)
Figure 38. Mexico Anti-TIGIT Antibody Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Brazil Anti-TIGIT Antibody Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. Middle East & Africa Anti-TIGIT Antibody Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Middle East & Africa Anti-TIGIT Antibody Market Share by Country (2019-2030)
Figure 42. Turkey Anti-TIGIT Antibody Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Saudi Arabia Anti-TIGIT Antibody Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. Roche Revenue Growth Rate in Anti-TIGIT Antibody Business (2019-2024)
Figure 45. Merck Revenue Growth Rate in Anti-TIGIT Antibody Business (2019-2024)
Figure 46. AstraZeneca Revenue Growth Rate in Anti-TIGIT Antibody Business (2019-2024)
Figure 47. Arcus Revenue Growth Rate in Anti-TIGIT Antibody Business (2019-2024)
Figure 48. Astellas Revenue Growth Rate in Anti-TIGIT Antibody Business (2019-2024)
Figure 49. BeiGene Revenue Growth Rate in Anti-TIGIT Antibody Business (2019-2024)
Figure 50. BMS Revenue Growth Rate in Anti-TIGIT Antibody Business (2019-2024)
Figure 51. Junshi Biosciences Revenue Growth Rate in Anti-TIGIT Antibody Business (2019-2024)
Figure 52. Innovent Biologics Revenue Growth Rate in Anti-TIGIT Antibody Business (2019-2024)
Figure 53. Mereo BioPharma Revenue Growth Rate in Anti-TIGIT Antibody Business (2019-2024)
Figure 54. Seattle Genetics Revenue Growth Rate in Anti-TIGIT Antibody Business (2019-2024)
Figure 55. Hengrui Medicine Revenue Growth Rate in Anti-TIGIT Antibody Business (2019-2024)
Figure 56. Compugen Revenue Growth Rate in Anti-TIGIT Antibody Business (2019-2024)
Figure 57. Gilead Sciences Revenue Growth Rate in Anti-TIGIT Antibody Business (2019-2024)
Figure 58. Bottom-up and Top-down Approaches for This Report
Figure 59. Data Triangulation
Figure 60. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
